ethyl 2,3-Diamino-2-methylpropionate | 213025-09-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: ethyl 2,3-Diamino-2-methylpropionate
• 英文别名: Ethyl 2,3-diamino-2-methylpropanoate
• CAS: 213025-09-3
• 化学式: C₆H₁₄N₂O₂
• mdl: MFCD19214478
• 分子量: 146.189
• InChiKey: PWUGOCIEWQUFQP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  78.3
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
  申请人：——

  公开号：US20030130188A1

  公开（公告）日：2003-07-10

  Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

  本发明揭示了一些化合物，可以抑制&bgr;-淀粉样肽的释放和/或合成，因此在治疗阿尔茨海默病方面具有实用性。本发明还揭示了包含抑制&bgr;-淀粉样肽释放和/或合成的化合物的制药组合物，以及使用这些制药组合物预防和治疗阿尔茨海默病的方法。
• COMPOUNDS FOR OPTICALLY ACTIVE DEVICES
  申请人：Merck Patent GmbH

  公开号：EP3133067A1

  公开（公告）日：2017-02-22

  The present invention relates to novel compounds, particularly to compounds comprising a photoactive unit, said novel compounds being particularly suitable for ophthalmic devices as well as to ophthalmic devices comprising such compounds.

  本发明涉及新型化合物，特别是包含光活性单元的化合物，所述新型化合物特别适用于眼科设备以及包含此类化合物的眼科设备。
• Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
  申请人：Medlyte, Inc.

  公开号：US20030027304A1

  公开（公告）日：2003-02-06

  Methods and compositions are disclosed that are useful for the prevention and/or treatment of cardiovascular and cardiac diseases and disorders, or damage resulting from surgical or medical procedures that may cause ischemic or ischemic/reperfusion damage in humans; and cardiovascular trauma. The beneficial effects of the compositions and methods are achieved through the use of pharmaceutical compositions that include agents that interfere with the production and/or biological activities of sphingolipids and their metabolites, particularly sphingosine (SPH) and sphingosine-1-phosphate (S-1-P). Also disclosed are methods for identifying and isolating therapeutic agents.

  所公开的方法和组合物有助于预防和/或治疗心血管和心脏疾病和失调，或可能导致人体缺血或缺血/再灌注损伤的手术或医疗程序造成的损伤；以及心血管创伤。这些组合物和方法的有益效果是通过使用药物组合物实现的，这些组合物包括干扰鞘磷脂及其代谢物，特别是鞘磷脂（SPH）和鞘磷脂-1-磷酸（S-1-P）的产生和/或生物活性的制剂。还公开了用于鉴定和分离治疗剂的方法。
• HETEROCYCLIC COMPOUNDS AND THEIR USE FOR INHIBITING $g(b)-AMYLOID PEPTIDE
  申请人：Elan Pharmaceuticals, Inc.

  公开号：EP0968198A1

  公开（公告）日：2000-01-05
• US6506782B1
  申请人：——

  公开号：US6506782B1

  公开（公告）日：2003-01-14